Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).

Abstract: The present invention relates to an antiviral dispersion liquid, a method for producing the same, and an antiviral formed product. This dispersion liquid contains copper compound fine particles and a stabilizer in a non-aqueous solvent, and the copper compound fine particles are coated with fatty acid. The copper compound fine particles are dispersed in a dispersion medium homogeneously and stably, thereby to exhibit efficiently the antiviral properties of the copper compound fine particles.

Abstract: A tooth paste composition comprising black cumin oil (Nigella sativa) and fluoride-doped bioactive glass, zinc oxide, and/or titanium oxide is disclosed.

Abstract: The invention provides an adjuvant for use in the prevention and/or treatment of an autoimmune disease.

Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).

Abstract: Room-temperature stable dosage forms for oral delivery of calcitonin are disclosed herein. Dosage forms for oral delivery of calcitonin with low water content are also disclosed herein. Further disclosed herein are methods for producing such room-temperature stable dosage forms and low-water content dosage forms. Methods of treatment comprising the administration of such room-temperature stable dosage forms and low-water content dosage forms are also disclosed herein.

Abstract: Embodiments of the present application relate to commercial manufacturing processes for making bupivacaine multivesicular liposomes (MVLs) using independently operating dual tangential flow filtration modules.

Abstract: A hydrating cosmetic composition for keratinous substrates that includes a stabilized anhydrous balm that includes at least one glycol humectant dispersed in a stabilized anhydrous fatty phase that includes at least one plant derived butter, a blend of structuring waxes, and a blend of fatty compounds and a surfactant.

Abstract: The present invention relates to an agent comprising anion-exchange groups that are suitable for adsorbing bacterial lipopolysaccharides (LPS) and/or lipoteichoic acids (LTA), for use in the prevention and/or treatment of inflammatory conditions and/or diseases of the oral cavity or in the vaginal region. The present invention also relates to a pharmaceutical composition that comprises an agent of this kind and can adhere to mucosa.

Abstract: The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.

Abstract: There are provided a cosmetic ink that can be applied to a light-transmitting sheet to form an image with high hiding power and a method for producing a cosmetic sheet using the cosmetic ink. There are also provided a cosmetic ink with good drying characteristics and a method for producing a cosmetic sheet using the cosmetic ink. Such a cosmetic ink contains a reflecting agent, a higher alcohol having 3 or more carbon atoms, purified water, and a binder. The cosmetic sheet includes a sheet and a film of a solidified product of the cosmetic ink formed on the sheet.

Abstract: An object of the present invention is to provide a microneedle array which is capable of suppressing aggregation of liposomes in a case where a water-soluble polymer is mixed with liposomes during production of the microneedle array and is capable of localizing a drug at a tip of a needle. According to the present invention, provided is a microneedle array including: a sheet; and a plurality of needles which are present on an upper surface of the sheet, in which each needle contains a water-soluble polymer, a drug, a liposome, and a salt, a zeta potential of the liposome is ?10 mV or less, the zeta potential is a zeta potential of a liquid obtained by diluting the liposome to 0.1 mg/mL with 10 mmol/L of a phosphoric acid aqueous solution having a pH of 7, and a content of the salt in a portion of each needle which contains the liposome is 2.5 mmol/g or less.

Abstract: The present disclosure generally relates to a skin care composition for providing ultraviolet (UV) protection to skin with desired sensory feels by the consumers. More specifically, the present disclosure relates to a UV-blocking skin care composition having both proper stringiness and proper viscosity.

Abstract: Compositions and methods for making and using proliposomal and liposomal formulations of chemotherapeutic agents are disclosed. The proliposomal and liposomal formulations of chemotherapeutics, as well as medicaments and dosage forms that include such formulations, can be used with treatment regimens for bladder cancer and urothelial cancer. Hence, the formulations, medicaments, and dosage forms of the invention are suitable to treat bladder cancers by intravesical administration and to treat urothelial cancers. The formulations according to the invention include (a) a taxane (e.g., paclitaxel, docetaxel) or cisplatin, (b) a first phospholipid, dipalmitoyl phosphatidylcholine (DMPC), and (c) a second phospholipid, dimyrsityl phosphatidyl glycerol sodium (DMPG). The proliposomal formulations form liposomes upon contact with an aqueous vehicle.

Abstract: Provided herein are pharmaceutical compositions containing (a) at least one liposome includes at least one vesicle-forming phospholipid; and (b) treprostinil encapsulated within the liposome. The ratio of treprostinil to phospholipid is equal to or higher than 0.035 and provides a controlled release of treprostinil. Also provided is the use of the pharmaceutical compositions to treat respiratory diseases.

Abstract: The present disclosure provides a method of inducing or promoting darkening of the skin and/or melanogenesis, a method of treating a skin condition or disorder, in particular hypopigmentation, comprising administration of a polycationic aliphatic amine, wherein said polycationic aliphatic amine preferably is putrescine, spermidine and spermine. The invention further includes corresponding methods of reducing or preventing darkening of skin and/or melanogenesis, or related methods of treating a skin condition or disorder, comprising administration of at least an inhibitor of polycationic aliphatic amine transport or synthesis, wherein said inhibitor is preferably trimer44NMe or difluoromethylornithine (DFMO) respectively.

Abstract: This invention relates to compositions useful for localized and sustained release of therapeutic agents, and more particularly to functionalized liposomes embedded in a polyelectrolyte multilayer. Methods of preparing the compositions, methods of treating diseases, devices, and pharmaceutical compositions comprising the compositions are also provided.

Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.

Abstract: A separation agent for avoiding and/or destroying microbial growth in a store for a liquid hydrocarbon is provided wherein an interface between a phase of a liquid hydrocarbon and a phase of water can be reduced. The agent has a density which is higher than the density of a liquid hydrocarbon and lower than the density of water. By using the agent, simple, economical, efficient and long-lasting avoidance and/or destruction of microbial growth in a store for a liquid hydrocarbon is ensured. The avoidance and/or destruction includes inhibition of the increase in the microorganisms already present in the store and/or the killing thereof and a high quality of the respective liquid hydrocarbon is ensured. A method for avoiding and/or destroying microbial growth in a store for a liquid hydrocarbon, and a store for a liquid hydrocarbon which is suitable for the avoidance and/or destruction of microbial growth are also disclosed.

Abstract: A bioactive borate glass composition including, for example: 30 to 60% B2O3; 0.5 to 20% ZrO2; 3 to 30% Na2O; 0.1 to 15% K2O; 0.1 to 15% MgO; 5 to 30% CaO; and 1 to 5% P2O5 in mole percents based on 100 mol % of the total composition. Also disclosed is a method of making and method of using the compositions and the bioactive borate glass dentin treatment formulations.